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This study describes the mechanism of antiviral action of the N-aminoimidazole derivatives which exclusively inhibit retroviruses such as
HIV-1, HIV-2, SIV and MSV. These antiretroviral compounds, with lead prototype NR-818, were found to inhibit HIV-1 replication at the
transcriptional level. Analysis of each individual step of viral transcription, including transcriptional activation mediated by NF-κB, the chromatin
remodeling process at the viral promoter and viral mRNA transcription mediated by RNAPII, showed that NR-818 was able to prolong the
binding of NF-κB to its consensus sequence. The compound also increased the acetylation of histones H3 and H4 within the nucleosome nuc-1 at
the transcription initiation site and inhibited the recruitment of viral Tat and the phosphorylation of the RNA polymerase II C-terminal domain
(RNAPII CTD) at the viral promoter upon stimulation of latently HIV-1-infected cell lines. As a result, viral mRNA expression and subsequent
viral p24 production in stimulated latently HIV-1-infected cell lines was suppressed by NR-818. These data suggest that the N-aminoimidazole
derivatives effectively inhibit the reactivation of HIV-1 and may contribute to the control of the latent HIV-1 reservoir.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV; N-aminoimidazole derivatives; Transcription; LTR promoter; Tat; Cyclin-dependent kinase (CDK)Introduction
The eradication or efficient control of the AIDS pandemic is
one of the most important challenges at the beginning of the 21st
century. Although advances in HIV treatment have markedly
reduced the morbidity and mortality rates among HIV-infected
individuals, the virus still cannot be eradicated because of drug
resistance and viral latency. A state of viral latency may be
established if productively HIV-infected, activated CD4+ Tcells
return to a resting state in which transcription of viral genes is
minimal. Despite their low occurrence (<107 per individual), a
fraction of resting memory CD4+ T cells containing integrated
proviral DNA can produce infectious virus upon stimulation.
Moreover, these cells can persist for at least 30 months in
individuals on highly active antiretroviral therapy (HAART),
suggesting that this cellular reservoir for HIV may represent one⁎ Corresponding author. Fax: +32 16 332131.
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doi:10.1016/j.virol.2007.03.036of the major barriers to total virus eradication in HIV-infected
patients receiving antiretroviral therapy (Chun et al., 1997a,
1997b; Finzi et al., 1997; Wong et al., 1997). Although HAART
alone cannot provide virus eradication, lifetime control of the
infection with other antiretroviral approaches may be feasible.
Therapeutic intervention at the level of HIV transcription seems
attractive as it would open the possibility to control the infection
in acutely—as well as in latently infected cells. Furthermore,
HIV transcription inhibitors may have great potential in anti-
HIV drug combination therapy because the virus may be forced
to remain latent for the life span of the cellular reservoir.
In this study, we describe the discovery of a new class
of HIV-1 transcription inhibitors that may contribute to the
control of the latent HIV-1 reservoirs. Originally, a series of
N-aminoimidazole derivatives were synthesized with similarity
to capravirine (S-1153) with the purpose to develop new non-
nucleoside reverse transcriptase inhibitors (NNRTIs) (Pauwels,
2004). Remarkably, only a few compounds were found to be
endowed with NNRTI properties whereas the majority of this
new class of compounds were found to be equipotent against
221M. Stevens et al. / Virology 365 (2007) 220–237the replication of HIV-1, an NNRTI-resistant HIV-1 strain
(containing mutations K103N and Y181C in RT), HIV-2 and
SIV. The most potent members of the N-aminoimidazoles
were also active against MSV-induced transformation of
embryo murine C3H/3T3 fibroblasts in vitro (Lagoja et al.,
2003). This very unusual spectrum of antiviral activity sug-
gested that the antiviral activity of these compounds is not
based on the inhibition of the RT polymerase activity as might
have been expected from the structural similarity with
capravirine. In this study, we demonstrated that the antire-
troviral compounds with prototype NR-818 interfered with
HIV-1 gene regulation at multiple steps after stimulation of
latently HIV-1-infected cells: (i) At the level of transcriptional
activation mediated by NF-κB, NR-818 was found to prolong
the binding of NF-κB to its consensus sequence. (ii) At the
level of nuc-1 disruption at the transcription start site, NR-818
caused an increased acetylation status of histones H3 and H4
within nuc-1. (iii) The transcriptional elongation process was
inhibited by NR-818 since Tat recruitment and Ser5 phos-
phorylation of the CTD of RNAPII was decreased. As a result,
viral mRNA expression and subsequent viral p24 production
in stimulated latently HIV-1-infected cell lines was suppressed
by NR-818. Since we observed that not only HIV-1 gene
transcription, but also TNF-α gene transcription was inhibited
by NR-818 in both infected and uninfected cells after stim-
ulation, we concluded that the N-aminoimidazole derivatives
interact with a cellular target located at the level of HIV-1
transcription, likely involving a cellular kinase.
Results
The N-aminoimidazole derivatives inhibit HIV-1 replication in
acutely and latently infected cells
Previously, we reported the antiviral activity of a series of
N-aminoimidazole derivatives against the replication of HIV-1,
an NNRTI-resistant HIV-1 strain (containing mutations
Lys103Asn and Tyr181Cys in RT), HIV-2 and SIV in MT-4
cells (Lagoja et al., 2003). Since the compounds had great
similarity to the well-known second-generation NNRTI capra-
virine (S-1153), a few N-aminoimidazoles behaved as typical
NNRTIs. For example, NR-775 proved to inhibit HIV-1 RT andTable 1
Inhibition of viral replication in MT-4 cells by the N-aminoimidazole derivatives
Compound EC50
a
HIV-1
IIIB NL4.3 NNRTI
NR-775 1.6±0.61 2.2±0.88 26±3
NR-777 0.72±0.59 0.63±0.03 0.38±0
NR-818 5.5±2.1 6.6±4.8 12±5
Data represent the average values (±SD) for at least three independent experiments.
a 50% effective concentration (μM), or compound concentration required to inhib
MTT method.
b 50% cytotoxic concentration (μM), or compound concentration that reduces the
c HIV-1 IIIB strain containing the double mutation Lys103Asn and Tyr181Cys into select for typical NNRTI-characteristic mutations in the HIV-1
RT of virus-infected cell cultures (Lagoja et al., 2003). In
addition, the data in Table 1 show that NR-775 loses antiviral
activity (>10-fold) against HIV-1 strains containing the double
mutation Lys103Asn and Tyr181Cys in the RT as compared to
wild-type HIV-1 strains. Remarkably, partial or even full
retention of anti-HIV-1 activity against the HIV-1 strain
containing the double NNRTI-characteristic mutation suggests
that the N-aminoimidazole derivatives must have a second
target of antiviral action independent of HIV-1 RT. In this
context, we selected two congeners among the N-aminoimida-
zoles that retained full antiviral activity against all retroviral
strains tested. As presented in Table 1, NR-777 and NR-818
were found to be equipotent against the replication of HIV-1,
the double mutant NNRTI-resistant HIV-1 strain, HIV-2 and
SIVMAC251.
In addition to this remarkable spectrum of antiviral activity
on acute infection of MT-4 cells, we evaluated the compounds
for their inhibitory effects on virus production in latently HIV-
1-infected OM-10.1 and U1 cells, as well as in their
uninfected corresponding HL-60 and U937 cell lineages
upon acute infection with HIV-1(IIIB). TNF-α, PMA and
TSA stimulation of these latently HIV-1-infected cell lines
caused a dramatic (∼1000-fold for TNF-α and PMA, and
∼100-fold for TSA) increase in HIV-1 expression, which was
set as one hundred percent (Fig. 1). As shown in Fig. 1, the N-
aminoimidazole derivatives NR-777 and NR-818 cased a dose-
dependent inhibition of HIV-1 p24 production from the latently
HIV-1-infected cell lines after stimulation with TNF-α, PMA
or TSA. This inhibitory effect was similar under the different
stimulation conditions. In order to take the pre-integrational
steps into account, we evaluated both compounds for their
inhibitory effects on the acute infection of the HL-60 and
U937 cell lines with HIV-1(IIIB). Antiviral data from both
acutely and latently HIV-1-infected promyelocytic (HL-60 and
OM-10.1) and promonocytic (U937 and U1) cells are
compared in Table 2. We clearly observe an identical
inhibitory effect in both viral infection models (acute or latent
HIV infection) which indicates that the anti-HIV-1 activities of
the compounds were exclusively targeted at the post-integra-
tional level in the replication cycle of the virus. This result was
confirmed by time-of-addition experiments in U937 cellCC50
b
HIV-2 SIV
(res) c ROD MAC251
.9 >36 6.5±4.6 >36
.28 0.72±0.03 0.31±0.13 12±9.9
.3 5.1±3.8 4.7±0.30 32±9.1
it virus-induced cytopathic effect by 50% in MT-4 cells, as determined by the
viability of mock-infected cells by 50%, as determined by the MTT method.
the viral RT.
Fig. 1. Inhibitory effect of N-aminoimidazole derivatives on TNF-α-, PMA- and TSA-induced expression of HIV-1 in OM-10.1 and U1 cells. The cells were incubated
with the compounds for 2 h, stimulated with either 1 ng/ml TNF-α (black bars), 0.02 μM PMA (grey bars) or 0.2 μM TSA (white bars) and further incubated for 48 h.
Supernatants were then collected for p24 antigen quantification and the p24 levels are expressed as the percent of control (no compound). Cell cultures were examined
for cell viability (♦) using the MTTmethod after a 2-day incubation period. All experiments were carried out in quadruplicate, and results are presented as mean values
with standard deviation.
222 M. Stevens et al. / Virology 365 (2007) 220–237cultures, in which the test compounds were added at different
time points after infection of the cell cultures with HIV-1(IIIB)
(Fig. 2). Reference compounds with a known mode of action
were included, such as detran sulfate that interferes with the
virus binding (0–1 h), AZT that inhibits HIV RT (2 to 4 h), the
diketo acid L-870,830 that inhibits the strand transfer step of
the integration process (7 to 8 h) and ritonavir that is an
inhibitor of the viral protease and can be added for up to 22 h
post-infection without loss of antiviral potency (Fig. 2).
Clearly, when the N-aminoimidazole NR-818 was added atTable 2
Inhibitory effects of the N-aminoimidazole derivatives in acutely and latently HIV-1-
cell lines
Compound HL-60 cells OM-10
EC50
a CC50
b EC50
TNF-α
NR-777 2.4±0.9 21±4.2 1.6±0.2
NR-818 4.8±2.1 ≥60 3.0±0.6
Compound U937 cells U1 cell
EC50
a CC50
b EC50
TNF-α
NR-777 1.5±0.3 23±6.9 1.5±0.0
NR-818 3.0±1.2 ≥60 1.2±0.1
Data represent the average values (±SD) for at least three independent experiments.
a 50% effective concentration (μM) or compound concentration required to achie
b 50% cytotoxic concentration (μM), or compound concentration that reduces thedifferent time points after viral infection, we found that ad-
ministration of the compound could be delayed for at least
12 h post-infection before loss of antiviral potency (Fig. 2). It
can therefore be concluded that the N-aminoimidazole
derivatives inhibit vral replication at a step in the replication
cycle of the virus beyond integration and prior to the viral
protease activity.
Finally, we evaluated the N-aminoimidazoles for their
inhibitory effects in acutely HIV-1-infected PBMCs, isolated
from healthy HIV-1-seronegative donors, and in human primaryinfected promyelocytic (HL-60 and OM-10.1) and promonocytic (U937 and U1)
.1 cells
CC50
PMA TSA
4 0.99±0.15 1.6±0.27 24±1.5
1.3±0.15 2.8±0.21 ≥60
s
CC50
PMA TSA
6 0.90±0.03 1.6±0.03 15±3.3
8 1.2±0.03 3.0±0.27 44±5.7
ve 50% reduction of p24 production in acutely or latently HIV-1-infected cells.
viability of mock-infected cells by 50%, as determined by the MTT method.
Fig. 2. Time-of-addition experiment. U937 cells were infected with HIV-1(IIIB)
and the test compounds were added at different times post-infection. Viral p24
production was determined at 36 h post-infection and is expressed as the log10 of
the p24 antigen levels in pg/ml. Symbols: (⋄) control; (▪) dextran sulfate; (▵)
AZT; (♦) L-870,830; (▴) NR-818; (□) ritonavir.
Table 3
Inhibitory effects of the N-aminoimidazole derivatives in human primary PBMC
and M/M cells
Compound PBMCs M/M
EC50
a CC50
b EC50
HIV-1(IIIB) HIV-1(NL4.3)
NR-777 1.0±0.24 1.4±0.12 21±14 0.24±0.18
NR-818 2.7±0.99 6.9±2.1 44±16 0.06±0.03
Data represent the average values (±SD) for at least two independent
experiments.
a 50% effective concentration (μM) or compound concentration required to
achieve 50% reduction of p24 production in HIV-1-infected PBMCs.
b 50% cytotoxic concentration (μM), or compound concentration that
reduces the viability of mock-infected cells by 50%, as determined by the
Trypan blue exclusion method.
223M. Stevens et al. / Virology 365 (2007) 220–237M/M cells (Table 3). Both N-aminoimidazole derivatives NR-
777 and NR-818 proved inhibitory against the replication of
HIV-1 in human PBMCs with selectivity indices up to 20.
Evaluation of both compounds against acute infection of the
HIV-1(BaL) strain in primary M/M cell cultures indicated that
the antiviral potency was markedly increased, in particular for
NR-818. Thus, the N-aminoimidazole derivatives represent a
class of anti-HIV agents with inhibitory properties against
multiple virus strains in different infection models.
The N-aminoimidazole derivatives are inhibitory to the HIV-1
transcription process in latently infected cells
In order to investigate the effect of the N-aminoimidazoles
on HIV-1 transcription, we quantified the full-length viral
transcripts produced after stimulation of latently HIV-1-infected
cells with TNF-α, PMA or TSA. In this context, we made a
construct containing a 93-bp fragment from the RT gene of
HIV-1 that served as standard for the quantification of the
population of full-length viral mRNAs. The low number of viral
transcripts quantified in unstimulated conditions were sub-
tracted from all stimulated samples once all data were
normalized using the quantification results obtained for the
endogenous control GAPDH. Following TNF-α, PMA or TSA
stimulation of the latently HIV-1-infected OM-10.1 and U1
cells, we observed a 1000-fold increase in viral mRNA
production. The samples representing the stimulation condition
in the absence of inhibitor were set as one hundred percent and
used as a reference to express the effect of the N-aminoimida-
zoles NR-777 and NR-818 on HIV-1 transcription in latently
HIV-1-infected cells (Fig. 3). As shown in Fig. 3, both com-
pounds were endowed with remarkable suppressive effects on
HIV-1 transcription in OM-10.1 and U1 cells after stimulation
with either TNF-α, PMA or TSA at non-cytotoxic concentra-
tions. For example, NR-777 and NR-818 inhibited viral mRNA
production in OM-10.1 cell cultures by 50% at a concentration
of 0.83 μM and 1.4 μM, respectively, when stimulated withTNF-α, while stimulation with PMA resulted in 50% inhibitory
values of 0.89 μM and 1.6 μM, respectively, and IC50 values of
1.5 μM in TSA-stimulated cell cultures. The dose-dependent
decrease of HIV-1 mRNA production observed in the OM-10.1
and U1 cells upon N-aminoimidazole treatment correlated well
with their inhibitory effect on viral p24 production from these
latently HIV-1-infected cells after stimulation with TNF-α,
PMA and TSA.
Analysis of the effect of the N-aminoimidazole derivatives on
transcriptional activation
The transcription of HIV-1 can be subdivided in different
stages including transcriptional activation mediated by the
NF-κB p50/p65 heterodimer, the chromatin remodeling
process at the viral promoter and the actual mRNA
transcription process mediated by RNAPII (for a review, see
Stevens et al., 2006). In order to investigate at which stage the
N-aminoimidazoles interfere with transcription, we analyzed
the effect of the compounds on each stage of the viral
transcription process. Initially, the transcriptional activation
process mediated by NF-κB was analyzed by investigating
NF-κB activation and DNA binding. Stimulation of latently
HIV-infected cells with TNF-α results in phosphorylation and
subsequent proteasome-mediated degradation of IκBα in the
cytoplasm to release NF-κB from the inactive complex (Beg
et al., 1992; Whiteside and Israel, 1997). As shown in Fig.
4A, the TNF-α-induced degradation of IκBα was completed
after 15 min in OM-10.1 cells. This results in the activation
and subsequent translocation of NF-κB to the nucleus where
it binds the HIV-1 LTR but also the IκBα and many other
promoters (Sun et al., 1993). As such, IκBα synthesis leads to
the full regeneration of IκBα within 60 min after TNF-α
stimulation as shown in Fig. 4A. Treatment of these TNF-α-
stimulated cell cultures with the N-aminoimidazoles NR-777
and NR-818 did not alter the degradation nor the regeneration
of IκBα. Additionally, translocation of NF-κB to the nucleus
upon release from IκBα was also not affected by the
compounds as observed by immunofluorescence microscopy
(Fig. 4B). Finally, we evaluated the N-aminoimidazoles for
their effect on NF-κB DNA binding with EMSA (Fig. 4C)
Fig. 3. Inhibitory effect of N-aminoimidazole derivatives on HIV-1 mRNA transcription in latently HIV-1-infected OM-10.1 and U1 cell lines after stimulation with
1 ng/ml TNF-α (black bars), 0.02 μM PMA (grey bars) and 0.2 μM TSA (white bars). Total RNAwas isolated from the cells by the TRIzol RNA extraction method.
Quantification of total viral RNAwas assessed by real-time PCR amplifying a 93-bp fragment from the RT gene of HIV-1 using the TaqMan technology. In order to
obtain the right HIV-1 mRNA amounts, correction was included using GAPDH as endogenous control. All experiments were carried out in quadruplicate, and results
are presented as mean values with standard deviation.
224 M. Stevens et al. / Virology 365 (2007) 220–237and ELISA (Fig. 4D). The latently HIV-infected OM-10.1
cells were cultured with NR-818, stimulated by TNF-α, and
nuclear extracts were examined for binding to the 32P-labeled
NF-κB oligonucleotide in the EMSA assay, as well as for
binding to the NF-κB consensus sequence bound to the 96-
well plates in the ELISA assay. As shown in Figs. 5C and D,
NF-κB binding was accomplished 15 min after TNF-α
stimulation of OM-10.1 cells, with maximal DNA binding
between 15 and 30 min post-stimulation. Once stimulation
conditions reached 60 min and beyond, DNA binding of the
transcription factor was decreased. This was due to the
regeneration of IκBα which removes NF-κB from the viral
promoter to transport it back to the cytoplasm leading to the
termination of the NF-κB-dependent viral transcription (Sun
et al., 1993). When TNF-α-stimulated OM-10.1 cells were
treated with NR-818, we clearly observed, in two independent
EMSA experiments, that NF-κB binding was prolonged as
compared to the untreated control (Figs. 5C and D, 1 out of 2
independent experiments presented). This remarkable result
was also corroborated through the ELISA method which
confirmed the prolonged binding of NF-κB to its consensus
sequence. In order to confirm that NF-κB is binding to the
32P-labeled NF-κB oligonucleotide in the EMSA assay,
supershift experiments with rabbit polyclonal anti-NF-κB
p65 antibodies were conducted on the TNF-α-stimulated
nuclear extracts (Fig. 4C).
Effect of N-aminoimidazole derivatives on histone acetylation
The position of nuc-1 at the transcription initiation site and
its disruption upon transcriptional activation suggests thatchromatin plays an essential role in the suppression of HIV-1
during latency (Van Lint et al., 1996; Sheridan et al., 1997).
Reactivation of the HIV-1 provirus may be mediated by the
displacement of histone deacetylases (HDACs), bound to NF-
κB p50/p50 homodimers, in response to the recruitment of
histone acetyltransferases (HATs) by transcriptionally active
NF-κB p50/p65 heterodimers (Williams et al., 2006). As such,
nuc-1 becomes rapidly and specifically disrupted by acetyla-
tion of specific lysine residues within histone H3 and H4 of
nuc-1. These histone acetylation events act then as signals for
the recruitment of chromatin remodeling complexes to disrupt
nuc-1 in a non-covalent manner (Angelov et al., 2002;
Henderson et al., 2004; Treand et al., 2006). Nuc-1 disruption
results in an open nucleosome-free region with subsequent
binding of transcription factors necessary for the assembly of a
pre-initiation complex (PIC) and initiation of RNAPII
transcription.
In order to investigate the disruption of nuc-1 from the HIV-
1 promoter, the acetylation process at the level of nuc-1 and
the subsequent remodeling event was analyzed. Initially, we
optimized a quantitative ChIP assay to examine the levels of
H3 and H4 acetylation in both latently HIV-1-infected OM-
10.1 and U1 cell lines. Since we wanted to look specifically
into the nuc-1 on the viral promoter, we developed a sonication
protocol to generate chromatin fragments that contain an
average length of 150 to 400 bp. The fragments are
approximately the size of an average nucleosome including
linker DNA. The antibodies used to precipitate these chromatin
fragments recognize either acetylated histone H3 (lysines 9 and
14) or acetylated histone H4 (lysines 5, 8, 12 and 16). We used
a primer set within nuc-1 to analyze the acetylation status of
225M. Stevens et al. / Virology 365 (2007) 220–237H3 and H4 by semi-quantitative PCR as well as real-time
TaqMan PCR. We found that TSA treatment for 30 min
increased the acetylation of H3 and H4 within nuc-1 two- to
three-fold in both latently HIV-1-infected cell lines (Figs. 6A
and B). Remarkably, when cell cultures were treated with NR-
818, we observed a further increase in nuc-1 acetylation in all
tested conditions in combination with TSA. We observed that
NR-818 further increased acetylation of H3 from 2.5-fold to 4-
fold whereas acetylation of H4 within nuc-1 was augmented by
another 0.5-fold in combination with TSA treatment. To
eliminate the possibility that differences in the levels ofFig. 4. Analysis of the effect of N-aminoimidazole derivatives on transcriptional
regeneration of IκBα from NF-κB. OM-10.1 cells were treated with TNF-α as such or
time (in min). The cytoplasmic lysates were prepared and fractionated on 4–12% N
N-aminoimidazoles on TNF-α-induced nuclear translocation of NF-κB. HeLa and O
of 30 μM NR-818. Then, the cells were fixed, permeabilized and examined by fluo
NR-818 on TNF-α-induced DNA binding of nuclear NF-κB. OM-10.1 cells were cult
time periods (min), nuclear extracts were prepared and analyzed for NF-κB binding b
binding sites, pre-incubation with a polyclonal antibody against NF-κB p65 was peacetylated histones are masked by nucleosome displacement,
we examined the levels of non-acetylated H3 by ChIP and
found no significant change within nuc-1 upon TSA or NR-
818 treatment (Fig. 5C).
Effect of N-aminoimidazole derivatives on nuc-1 remodeling
Next, we evaluated the effect of NR-818 on the remodeling
of nuc-1 at the start site of HIV-1 transcription and used a
modified approach of Verdin and coworkers (1996) which was
based on Taqman PCR technology. Nuclei were prepared fromactivation. (A) Effect of the compounds on TNF-α-induced degradation and
in the presence of 15 μMNR-777 or 30 μMNR-818 for the indicated periods of
ovex Bis–Tris gels and analyzed for the presence of IκBα. (B) Effect of the
M-10.1 cells were treated with TNF-α for 30 min in the presence or absence
rescence microscopy upon NF-κB p65 and DAPI staining. (C and D) Effect of
ured with 30 μMNR-818 for 1 h. Following TNF-α stimulation for the indicated
y EMSA and ELISA. In order to determine the specificity of NF-κB for its DNA
rformed to generate a supershift.
Fig. 4 (continued).
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and/or HinfI (Fig. 6A). DNA was purified from the nuclei and
analyzed with the nuc-1 primer set for digestion whereas an
undigested site in the proviral DNAwas used as internal control.
As shown in Fig. 6B, the region corresponding to nuc-1 became
accessible to digestion by AflII, HindIII and/or HinfI following
treatment with TNF-α since we quantified less PCR product as
compared to the untreated control. Stimulation of both latently
HIV-1-infected cell lines was performed with TNF-α instead of
TSA, because the overnight incubation period with TNF-α
resulted in better cell viability and more consistent results.Fig. 5. Effect of N-aminoimidazole derivatives on the acetylation of H3 and H4 his
presence or absence of 30 and 15 μMNR-818, respectively, and stimulated with 0.2 μ
to generate chromatin fragments of between 150 and 400 bp. The sonicated lysates w
semi-quantitative and quantitative PCR. A portion of each lysate was used as contr
latently HIV-1-infected cell lines were also grown and analyzed as described above b
acetylated histone H3 (C). The levels of acetylation are an average of at least two inde
and LTR-R were used to amplify nuc-1 DNA which was recognized by the FAM/TAClearly, as we used combinations of the restriction enzymes, the
digestion after TNF-α stimulation was further enhanced with
the lowest amounts of nuc-1 PCR product when all three
restriction enzymes were used to cleave nuc-1 proviral DNA.
Following treatment with NR-818, we did not observe any
marked change in digestion pattern which indicates that nuc-1
remodeling after stimulation is not altered by the compound.
Additionally, we used a control restriction enzyme ScaI, that
cuts proviral DNAwithin the internucleosomal region between
nuc-0 and nuc-1, accessible both in unstimulated and stimulated
cells.tones associated with nuc-1. OM-10.1 (A) and U1 (B) cells were grown in the
M TSA for 30 min. The cells were fixed with formaldehyde, lysed and sonicated
ere then immunoprecipitated with the indicated antibodies and processed in both
ol to normalize the amount of input DNA between experimental samples. Both
ut sonicated lysates were immunoprecipitated with an antibody specific for non-
pendent experiments and expressed as fold induction. The nuc-1 primers LTR-F
MRA-labeled TaqMan LTR probe.
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Fig. 6. Effect of the N-aminoimidazole derivatives on nuc-1 remodeling. (A) Diagram shows the positions of nucleosomes bound to the HIV-1 LTR and the location of
the restriction recognition sites (Verdin et al., 1993). (B) OM-10.1 and U1 cells were grown in the presence and absence of 30 and 15 μM NR-818, respectively, and
stimulated with 1 ng/ml TNF-α. Upon overnight incubation, nuclei were prepared from the cells and partially digested with the indicated restriction enzymes. DNA
was purified and analyzed with the primers LTR-F and LTR-R for nuc-1 digestion whereas an undigested site in the RT gene of the proviral DNAwas used as internal
control. Using the FAM/TAMRA-labeled TaqMan LTR probe and the VIC/TAMRA-labeled TaqMan HIV-RT probe, proviral DNAwas quantified and compared to
the untreated control.
228 M. Stevens et al. / Virology 365 (2007) 220–237Inhibitory effect of N-aminoimidazole derivatives on viral Tat
recruitment to the HIV-1 promoter and Ser5-dependent RNAPII
transcription
Since the N-aminoimidazole derivatives were not found to
inhibit transcriptional activation nor nuc-1 disruption, we
investigated the effect of the compounds on the viral
transcription process. Following nuc-1 disruption at the start
site of transcription, the viral promoter becomes accessible to
multiple transcription factors necessary for the assembly of the
PIC. Within this complex, RNAPII can be found that catalyzes
the synthesis of viral mRNA from the proviral DNA. The
processivity of RNAPII-mediated transcription can be asso-
ciated to the phosphorylation status of the CTD of RNAPII that
contains multiple-tandem repeats of the YSPTSPS heptapep-
tide, with both Ser2 and Ser5 known to be sites of reversible
phosphorylation. As such, the CDK7 activity of the transcrip-
tion factor TFIIH phosphorylates the fifth serine of the
heptapeptide repeat present in the CTD of RNAPII (Serizawaet al., 1995; Shiekhattar et al., 1995), whereas CDK9, which can
be recruited to the viral promoter by NF-κB, is able to catalyze
the phosphorylation of the second serine of the heptapeptide
repeat (West et al., 2001; Barboric et al., 2001). Although
CDK9 phosphorylates Ser2 of the CTD of RNAPII, the
presence of Tat modifies the substrate specificity of CDK9
enabling the kinase to phosphorylate both Ser2 and Ser5 of the
CTD (Herrmann and Rice, 1993, 1995; Zhu et al., 1997; Zhou
et al., 2000; Kim et al., 2002). This results in a hyperpho-
sphorylated CTD of RNAPII leading to a highly productive
elongation of transcription generating full-length viral tran-
scripts. In order to analyze the effect of N-aminoimidazole
derivatives on viral transcription, we performed ChIP experi-
ments using antibodies directed towards HIV-1 Tat (Hauber et
al., 1987) and the CTD of RNAPII (Jones et al., 2004). As
shown in Fig. 7, TNF-α stimulation of latently HIV-1-infected
OM-10.1 and U1 cells resulted in the recruitment of viral Tat to
the HIV-1 promoter (Fig. 7A) and caused an increased Ser5
phosphorylation status of the RNAPII CTD (Fig. 7B).
Fig. 7. Inhibitory effect of N-aminoimidazole derivatives on the recruitment of the viral Tat protein to the HIV-1 promoter and on the subsequent Ser5 phosphorylation
of the RNAPII CTD. OM-10.1 and U1 cells were treated with 30 and 15 μMNR-818, respectively, or 1 μg/ml WM-14 followed by TNF-α stimulation to induce viral
transcription. Transcription complexes were immunoprecipitated with the HIV-1 Tat antiserum (A), α-CTD H14 (B) and 8WG16 (C) antibodies according to the ChIP
protocol and processed for both semi-quantitative and quantitative PCR using nuc-1 primers LTR-F and LTR-R and the FAM/TAMRA-labeled TaqMan LTR probe.
The levels of RNAPII CTD phosphorylation are an average of at least two independent experiments and expressed as fold induction.
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230 M. Stevens et al. / Virology 365 (2007) 220–237Treatment of TNF-α-stimulated cell cultures with NR-818
resulted in an inhibitory effect on both the Tat recruitment as
well as the phosphorylation status of RNAPII which was as
pronounced as observed with the known Tat-TAR transcription
inhibitor WM-14 (Stevens et al., 2005). Finally, the unpho-
sphorylated RNAPII was also targeted by antibodies in the ChIP
assay and found to be present in both stimulated and
unstimulated transcription complexes.
The N-aminoimidazoles interfere with a cellular rather than a
viral target
Since we found that the N-aminoimidazoles were able to
inhibit the Tat-mediated RNAPII processivity, we conducted
gene expression experiments using the GFP reporter gene
linked to the HIV-1 LTR promoter. Initially, we transfected
Jurkattat cells with the pLTRGFP construct and quantified Tat-
mediated GFP gene expression from the viral LTR promoter.
Remarkably, increasing concentrations of NR-818 resulted in a
stimulation of gene expression even at toxic concentrations of
the compound (Fig. 8). When the experiments were repeated
in Jurkat wild-type cells transiently transfected with a Tat-
expressing construct and the reporter construct pLTRGFP, a
similar dose-dependent increase in GFP production could be
observed. Since both experiments involve viral Tat, we were
interested to know whether the stimulatory effect of NR-818
on GFP gene expression could also be reproduced in Jurkat
wild-type cells in the absence of Tat (Fig. 8). Indeed, the Tat-
independent LTR-mediated gene expression in these TNF-α-
stimulated Jurkat wild-type cells was also increased upon
NR-818 treatment. These findings point to the lack of a
significant specific role of Tat in the stimulatory properties of
NR-818. In order to confirm these findings, we also performed
the GFP gene expression experiments in HeLa cell lines all or
not stably transformed with Tat and found similar results as
observed with the Jurkat cells. As shown in Fig. 8, expression of
GFP was markedly induced in HeLa cells transformed or
transiently transfected with Tat upon NR-818 treatment. In order
to investigate the antiretroviral activity of the compound in theseFig. 8. Effect of the N-aminoimidazole derivatives on GFP gene expression mediated
(black bars), Jurkat wt cells transfected with the Tat-expressing construct (grey bars)
the absence or presence of NR-818 for 24 h. Right graph, HeLa (black bars), CD4+ H
construct and, in case of the first two HeLa cell lines, also with the Tat-express
Quantification of GFP production was measured with the Fluorocount and expresse
cultures by the MTT method. Results are presented as mean values of at least threeHeLa cells, we evaluated NR-818 for its effect on acute infection
of the CD4+ HeLa cells with HIV-1(IIIB) and found a potent anti-
HIV activity of NR-818 against virus replication with an EC50
value of 1.0 μM. Virus production (as measured by p24
detection) was completely inhibited by the compound in the
concentration range as indicated in Fig. 8. For example, non-
toxic concentrations of 3.75 and 7.5 μM NR-818 resulted in an
inhibitory effect on HIV-1 replication of 90% and 100%,
respectively. This discrepancy between inhibitory and stimula-
tory effects on HIV-1 LTR-driven gene expression may indicate
that the target of antiviral action of theN-aminoimidazoles likely
depends to the presence of nucleosomal arrangements on the
viral promoter.
Since the GFP gene expression experiments demonstrate the
presence of a nucleosomal arrangement on the promoter to be a
prerequisite in the inhibitory effect of NR-818, we wanted to
confirm these findings by evaluating the effect of the N-
aminoimidazoles on the expression of other inducible genes
besides HIV-1 after stimulation. In this context, we quantified
the production of hTNF-α protein and the expression of hTNF-α
mRNA after stimulation of latently HIV-infected OM-10.1 cells,
as well as the uninfected equivalent HL-60 cell lineage, with
PMA. As shown in Fig. 9, both N-aminoimidazole derivatives
NR-777 and NR-818 inhibited the release of cellular TNF-α in
the supernatants of PMA-stimulated latently HIV-infected cells
at non-toxic concentrations. As these cells are infected with
HIV-1 with possible involvement of viral proteins such as Tat,
we also investigated whether the inhibitory effect of the N-
aminoimidazoles on cellular gene expression could be repro-
duced in the uninfected equivalent cell line. Indeed, we found
identical inhibitory potencies for NR-777 andNR-818 on hTNF-
α production in HL-60 cells, which indicates that the target of
inhibition is independent of viral infection (Fig. 9). Since we
proved that the N-aminoimidazole derivatives inhibit HIV-1
replication at the level of transcription, we also evaluated
whether the inhibition of hTNF-α production by the compounds
was also caused by interference at the transcriptional level of the
hTNF-α gene. In this context, we made a construct that
contained the complete gene of hTNF-α that served as standardfrom the HIV-1 LTR promoter. Left graph, Jurkat wt cells stimulated with TNF-α
and Jurkattat cells (white bars) were transfected with pLTRGFP and incubated in
eLa (grey bars) and HLtat (white bars) cells transfected with the GFP-expressing
ing construct and incubated in the absence or presence of NR-818 for 24 h.
d as the percent of control. Cell viability (♦) was determined in the same cell
independent experiments with standard deviation.
Fig. 9. Effect of N-aminoimidazole derivatives NR-777 and NR-818 on hTNF-α production (upper panel) and hTNF-α mRNA transcription (lower panel) upon
stimulation of latently HIV-infected OM-10.1 cells (black bars) as well as the uninfected equivalent HL-60 cell line (white bars) with 0.02 μM PMA.
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gene expression assay. Upon PMA stimulation of both infected
and uninfected cell lines, we observed a 10-fold increase in
cellular TNF-α mRNA expression. The samples reflecting the
stimulation condition without compound was expressed as one
hundred percent and used as a reference to investigate the effect
of NR-777 and NR-818 on the expression of hTNF-α mRNA.
As shown in Fig. 9, both compounds were inhibitory to the
transcription of cellular TNF-α. Consequently, wemay conclude
that the N-aminoimidazole derivatives inhibit gene expression
likely by interfering with a cellular rather than a viral target.
In search for the cellular target, we evaluated the most relevant
cellular enzymes involved in HIV-1 gene regulation (Stevens et
al., 2006) for their susceptibility to NR-818. As expected andTable 4
Effect of NR-818 on a panel of kinases and histone acetyltransferases (HAT)
Protein kinase or
HAT enzyme
Residual activity in the
presence of NR-818
p300 (H3 peptide) 88
p300 (H4 peptide) 100
P/CAF (H3 peptide) 99
P/CAF (H4 peptide) 103
CDK1/cyclin B 84±1
CDK2/cyclin A 78±3
CDK2/cyclin E 68±6
CDK3/cyclin E 97±1
CDK5/p25 99±4
CDK5/p35 96±3
CDK7/cyclin H 107±2
CDK9/cyclin T1 90±5
Protein kinase and HAT activity (% of control) in the presence of 15 μM
N-aminoimidazoles and 10 μM ATP (for kinase profile). Activities are given as
the mean of duplicate determinations relative to control incubations in which the
inhibitor was substituted with DMSO. CDK, cyclin-dependent kinase.shown in Table 4, NR-818 exhibited no inhibitory effect on the
histone acetyltransferase (HAT) activity of p300 or P/CAF
whereas anacardic acid, a potent acetyltransferase inhibitor
(Balasubramanyam et al., 2003), was inhibitory to both HAT
enzymes. Next, we evaluated the effect of NR-818 on the most
relevant kinases involved in HIV-1 gene regulation, i.e., the
cyclin-dependent kinases (CDKs). Although we did not observe
any significant inhibitory effect of NR-818 on the panel of CDKs,
a moderate inhibition on CDK2-cyclin E activity was observed.
Discussion
Resting memory CD4+ T cells containing integrated provirus
are considered as the most important (dormant) cellular
reservoir for HIV-1. This viral reservoir is of serious concern
since these cells serve as a potential source of viral rebound and
remain one of the major obstacles for the eradication of HIV-1
in patients receiving HAART. Although the ultimate goal must
be to cure the HIV infection, development of alternative and/or
complementary antiretroviral strategies remains crucial in order
to prevent viral reactivation from the latent reservoir and as such
gain control over HIV-1 latency in HIV-infected individuals
(Chun et al., 1997a, 1997b; Zhang et al., 2000).
In this study, we describe the antiviral mechanism of the
N-aminoimidazole derivatives that may contribute to the control
of HIV-1 infections. Several N-aminoimidazoles, such as NR-
777 and NR-818, were found to be equipotent against the
replication of HIV-1, NNRTI-resistant HIV-1 strains, HIV-2 and
SIV. This antiviral activity spectrum suggests that the anti-
retroviral activity of these compounds is not based on the
inhibition of RTas might have been expected from the structural
similarity of the N-aminoimidazole derivatives with the known
NNRTI capravirine. Indeed, we proved that these N-
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the post-integrational level by inhibiting HIV-1 mRNA
transcription. Since HIV-1 transcription consists of multiple
steps including transcriptional activation mediated by NF-κB,
chromatin remodeling at the viral promoter and viral mRNA
transcription mediated by RNAPII (Stevens et al., 2006), we
investigated the effect of the N-aminoimidazoles on these
different stages in order to further pinpoint the exact mechanism
of antiviral action. Although the compounds enhanced NF-κB
binding and nuc-1 remodeling at the HIV-1 promoter, viral
mRNA transcription was markedly inhibited at similar drug
concentrations. We clearly observed a potent inhibitory effect of
the N-aminoimidazole derivatives on the recruitment of Tat to
the HIV-1 promoter, as well as on the transcriptional processivity
of RNAPII in the viral transcription process. As such, we may
conclude that the N-aminoimidazoles inhibit HIV-1 transcrip-
tional elongation and likely interact with a target prior to these
events. In order to investigate the involvement of Tat in the
mechanism of antiviral action, we performed GFP gene
expression experiments in the presence of the compounds and
observed stimulatory effects on GFP production from the HIV-1
LTR promoter. Since viral replication was still inhibited by the
N-aminoimidazoles, the discrepancy between the inhibitory
and the stimulatory effects on LTR-driven gene expression may
indicate that the interference of the N-aminoimidazoles with
HIV-1 gene expression likely leads to a different outcome
depending on the presence or the absence of nucleosomal
arrangements on the viral promoter. On the one hand, this may
involve stimulatory effects of the N-aminoimidazole derivatives
on GFP gene expression based on the prolonged binding of NF-
κB to the HIV-1 LTR promoter. On the other hand, the inhibitory
effects of theN-aminoimidazole derivatives on LTR-driven gene
expression may be limited to a chromatin-dependent environ-
ment in which the target of inhibition is posterior to NF-κB
binding and nuc-1 remodeling.
Since we showed the presence of a chromatin structure to be a
prerequisite for the inhibitory properties of the N-aminoimida-
zoles, we investigated whether the compounds inhibited not only
specifically HIV-1 gene expression but also other cellular events.
We analyzed the expression of a cellular gene, hTNF-α, in the
presence and absence of HIV-1 and observed an inhibitory effect
of the N-aminoimidazoles at the transcriptional level of hTNF-α
gene expression. Although hTNF-α transcription was sup-
pressed in both infected and uninfected cells by the N-
aminoimidazoles, the compounds were not found to interfere
with a variety of gene expression processes. For example, the N-
aminoimidazoles were not inhibitory to the regeneration of IκBα
protein at a concentration that inhibited virus replication. We
may therefore conclude that the N-aminoimidazole derivatives
are likely to be inhibitory to the expression of a well-defined
subset of cellular genes, including HIV-1 gene expression.
In search for the cellular target, we evaluated the N-amino-
imidazole derivatives for their effects on the most relevant
cellular enzymes involved in HIV-1 gene regulation (Stevens et
al., 2006). Although we could not observe any significant
inhibitory effect of the compounds on HAT or CDK activity, a
moderate inhibition of 32% on CDK2-cyclin E activity wasobserved at NR-818 drug concentrations of 15 μM. Since higher
concentrations of NR-818 resulted in compound precipitation,
and EC50 values of NR-818 in HIV-1-infected cell cultures are
restricted in the range of 1 to 5 μM, it may be possible that these
properties contribute to the low inhibition profile of NR-818
against CDK2 in vitro. Furthermore, the artificial set-up of the in
vitro kinase assays compared to the CDK activity in vivomay as
well underscore the inhibitory potency of the compound against
CDK2-cyclin E. For example, first-generation NNRTIs such as
nevirapine inhibit HIV-1 replication in cell culture at drug
concentrations that are significant lower compared to the
inhibitory potency against HIV-1 RT in an in vitro assay.
CDK2-cyclin E has been demonstrated to phosphorylate the
CTD of the RNAPII on the HIV-1 promoter (Deng et al., 2002)
as well as Tat both in vitro and in vivo (Ammosova et al., 2005,
2006), which clearly points to the relevance of this kinase in
Tat-mediated transcription. CDK2 has also been proven to be
dispensable for cell survival and normal development which
makes this cellular kinase an attractive and safe cellular target
for HIV drug development (Ortega et al., 2003; Berthet et al.,
2003). In addition to CDK2, it has also been demonstrated that
E type cyclins (cyclin E1 and E2) were largely dispensable for
cell proliferation and development (Geng et al., 2003; Mendez,
2003). For these reasons, the CDK2-cyclin E complex
represents a viable target to inhibit HIV-1 in both acutely and
chronically infected cells. Thus, CDK inhibitors may have great
potential in anti-HIV drug combination therapy because they
can force the virus to slow down its replication rate or even shut-
off replication and establish a dormant state.
Materials and methods
Compounds and plasmid constructs
The chemical structures of the studied N-aminoimidazole
derivatives are shown in Fig. 10. The compounds were synthe-
sized as previously described (Lagoja et al., 2003). Plasmids
used in this study include pHIV-GFPemd that contains the green
fluorescence protein (GFP) reporter gene driven by the HIV-1
LTR promoter (Daelemans et al., 2001) and pSV2tat72 obtained
from Dr. Alan Frankel through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH
(Frankel and Pabo, 1988). The construct pHIV-RT-Q was made
as follows. After a reverse transcription reaction on total RNA
isolated from OM-10.1 cells to cDNA, a PCR was performed
with forward primer HIV-RT-F CATTCCTTTGGATGGGT-
TATGAA and reverse primer HIV-RT-RTGTCATTGACAGTC
CAGCTGTCT in order to amplify a 93-bp fragment from the
HIV-1 RT gene for cloning into the TOPO cloning vector
(Invitrogen, Merelbeke, Belgium). The construct pTNF-Q was
constructed by cloning the complete TNF-α gene from the
cDNA mix with forward primer TNF-F GCTAAGAGGGAGA-
GAAGCAACTAC and reverse primer TNF-R GAAGAGGT-
TGAGGGTGTCTGAAG into the TOPO cloning vector. The
construct pLTR-Q was made by amplification of a 105-bp
fragment from the HIV-1 TAR regionwith forward primer LTR-F
GCTAACTAGGGAACCCACTGCTTA and reverse primer
Fig. 10. Structural formulae of the N-aminoimidazole derivatives used in this study.
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into the TOPO cloning vector. All constructs were checked by
sequencing and used as standard for quantitative real-time PCR.
pGAPDH-Q was used as internal control in the quantitative
real-time PCR reaction and was constructed by cloning the
complete GAPDH gene from the cDNA mix with forward
primer GAPDH-F GACAGTCAGCCGCATCTTAT and reverse
primer GAPDH-R CTTCCTCTTGTGCTCTTGCTG into the
TOPO cloning vector. This construct was also verified by
sequencing. Dextran sulphate with an average molecular weight
of 5000 was purchased from Sigma (Bornem, Belgium).
AMD3100 was obtained from Dr. G. Henson (then at
AnorMED, Langley, British Columbia, Canada). Nevirapine
(BI-RG-587; dipyridodiazepinone) was provided by Dr. P.
Ganong (Boehringer Ingelheim, Ridgefield, CT) and zidovudine
(AZT) was from Sigma (Bornem, Belgium). The diketo acid L-
870,830 was kindly provided by Dr. N. Neamati and Dr. T. R.
Burke (National Institutes of Health, Bethesda, MD). Ritonavir
(ABT538) was kindly provided by J. M. Leonard (Abbott
Laboratories, Abbott Park, IL).
Cells and viruses
The latently HIV-1-infected promyelocytic OM-10.1 cell line
(Butera et al., 1991), the latently HIV-1-infected promonocytic
U1 cell line (Folks et al., 1987) and the uninfected corresponding
HL-60 and U937 cell lineages were maintained in RPMI-1640
medium (Life technologies, Merelbeke, Belgium), supplemen-
ted with 10% heat-inactivated fetal calf serum (FCS, Integro,
Zaandam, The Netherlands), 2 mM L-glutamine (Life technol-
ogies) and 0.1% NaHCO3 (Life technologies) and incubated at
37 °C in a humidified CO2-controlled atmosphere. This RPMI-
1640 culture medium was also used to maintain MT-4 cells
which were provided by Dr. N. Yamamoto (Tokyo Medical
School and Dental University School of Medicine, Tokyo,
Japan). HLtat cells (contributed by Dr. B. K. Felber and Dr. G. N.
Pavlakis; National Institutes of Health, Bethesda, MD) and
Jurkattat cells (Caputo et al., 1990) are HeLa and Jurkat cells
stably expressing HIV-1 Tat protein, respectively. HeLa and
HLtat cells, as well as HeLa CD4
+ cells obtained from Dr.
Richard Axel through the AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH (Maddon et
al., 1986), were maintained in Dulbecco's modified Eagle'smedium (DMEM) supplemented with 10% FCS, whereas Jurkat
and Jurkattat cells were maintained in RPMI-1640 medium
containing 10% FCS, 2 mM L-glutamine and 0.1% NaHCO3.
Human primary monocyte/macrophages (M/M) were prepared
and purified as follows. Peripheral blood mononuclear cells
(PBMCs) were isolated from healthy HIV-1-seronegative
donor buffy coats using a Ficoll gradient (Lymphoprep;
Axis-Shield, Oslo, Norway), resuspended in RPMI-1640
supplemented with 2 mM L-glutamine, 15% FCS and 0.1%
NaHCO3, and spread out on IgG-immobilized Petri dishes.
After an incubation period of 3 days at 37 °C, M/M were
trypsinized and transferred to 24-well plates for antiviral
activity assays with the HIV-1(BaL) strain. The HIV-1 strain
IIIB (Popovic et al., 1984) was provided by Dr. R. C. Gallo and
Dr. M. Popovic (when at the National Institutes of Health,
Bethesda, MD).
Cytotoxicity and antiviral activity assays
The activity values of the N-aminoimidazole derivatives
against chronic HIV-1 infection were based on the inhibition of
p24 antigen production in OM-10.1 and U1 cells after
stimulation with TNF-α (Roche Diagnostics Belgium), PMA
(Sigma Chemical Co., Bornem, Belgium) and TSA (Sigma
Chemical Co., Bornem, Belgium). Briefly, OM-10.1 and U1
cells (5.105 cells/ml) were incubated in the presence or absence
of the compounds for 2 h in 48-well plates. After this short
incubation period, the cell cultures were stimulated with 1 ng/ml
of TNF-α, 0.02 μMof PMA or 0.2 μMTSA followed by transfer
of 2 times 200 μl into a 96-well plate for cytotoxicity evaluation.
After a 2-day incubation at 37 °C, the cell culture supernatants
were collected from the 48-well plates and examined for their
p24 antigen levels with the HIV-1 p24 ELISA kit (NEN,
Brussels, Belgium). Cytotoxicity of the compounds for both
latently HIV-1-infected OM-10.1 andU1 cell lines in the 96-well
plates were based on MTT cell viability staining, as described
previously (Pauwels et al., 1988).
Evaluation of the antiviral activity of the N-aminoimidazole
derivatives against acute HIV-1(IIIB) infection in HL-60, U937
and HeLa CD4+ cells was based on viral p24 antigen
determination using the HIV-1 p24 ELISA kit (NEN, Brussels,
Belgium). HL-60 and U937 cells were suspended at 300,000
cells/ml in RPMI-1640 culture medium, whereas HeLa CD4+
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per cup in DMEM culture medium. Upon infection with HIV-1
(IIIB) at approximately 100 times the 50% cell culture infectious
dose (CCID50) per ml for a period of 2 h, cells were washed 3
times and incubated at 37 °C in the presence or absence of the
compounds for 3 days.
For the antiviral activity assays in PBMCs, 106 cells/ml were
plated in the presence of serial dilutions of the test compounds
and were infected with HIV stocks at 1000 CCID50 per ml
(titrated on MT-4 cells). At day 4 post-infection, 125 μL of the
supernatant of the infected cultures was removed and replaced
by 150 μL of fresh medium containing the test compound at the
appropriate concentration. At 7 days after plating the cells, p24
antigen was detected in the culture supernatant by the HIV-1
p24 ELISA kit (NEN, Brussels, Belgium).
For the antiviral activity assay in M/M, 24-well plates seeded
with 150,000 cells per well were treated with various con-
centrations of compounds and infected with 100 CCID50 of
HIV-1(BaL)/ml. After a 5-day incubation period, culture
medium was replaced with fresh complete medium containing
the appropriate compound concentrations and the M/M were
then cultured for an additional 8 days. Supernatants were
finally collected for assessment of virus production by analysis
of HIV-1 p24 antigen (NEN, Brussels, Belgium).
Time-of-addition experiments in U937 cells
U937 cells were infected with HIV-1(IIIB) at a multiplicity of
infection (moi) of 0.5. The test compounds were added at
different time points after infection at approximately 100 times
their 50% inhibitory concentration. Viral p24 antigen produc-
tion was determined at 36 h post-infection by the HIV-1 p24
ELISA kit (NEN, Brussels, Belgium).
TNF-α quantification assay
The latently HIV-1-infected OM-10.1 and U1 cells, as well
as the uninfected equivalent HL-60 and U937 cells, were
stimulated with 0.02 μM PMA and cultured in the presence of a
dilution series of the test compounds. After a 24-h incubation
period at 37 °C, the cell culture supernatants were collected and
examined for their TNF-α concentrations using the TNF-α
ELISA kit (Roche Diagnostics Belgium) (Poli et al., 1990).
Quantitative real-time PCR
The quantitative determination of full-length HIV-1 mRNA
and cellular TNF-α mRNA in latently HIV-1-infected OM-10.1
and U1 cell lines was assessed by real-time detection based on
the TaqMan technology using the plasmid pHIV-RT-Q and
pTNF-Q, respectively, as standard and pGAPDH-Q as internal
control. Cells were seeded in 24-well plates at a density of
750,000 cells per well and were exposed to different concentra-
tions of the compounds for 1 h. Then, 1 ng/ml of TNF-α,
0.02 μMof PMAor 0.2 μMof TSAwas added to the cell cultures
followed by further overnight incubation at 37 °C. The next day,
cells were collected and RNA was extracted using the TRIzolmethod (Invitrogen, Merelbeke, Belgium). The PCR reactions
were performed in 96-well optical reaction plates with final
volumes of 25 μl per well. The PCR reaction for quantitative
determination of full-length HIV-1 mRNA contained 5 μl RNA
sample added to a mixture of 12.5 μl of TaqMan one-step RT-
PCR master mix, 1.25 μl endogenous GAPDH control mixture,
600 nM of each primer HIV-RT-F and HIV-RT-R and 250 nM of
the TaqMan HIV-RT probe ATAAATGGACAGTACAGCC
TATAGTGCTGCCAGA with the reporter dye 6-carboxyfluor-
escein (FAM) at the 5′-end and the quencher dye 6-carboxyte-
tramethylrhodamine (TAMRA) at the 3′-end. The PCR reaction
for quantification of cellular TNF-αmRNA contained 5 μl RNA
sample added to a mixture of 12.5 μl of TaqMan one-step RT-
PCR master mix, 1.25 μl endogenous GAPDH control mixture
and 1.25 μl TNF-α Assay-on-Demand mix that consists of
unlabeled PCR primers and a TaqMan MGB probe which is
FAM dye-labeled. The real-time PCR reaction performed on the
ABI Prism 7700 Sequence Detection System (Applied Biosys-
tems, Foster City, CA) was as follows: 30 min at 48 °C for
reverse transcription, 10 min at 95 °C for enzyme activation, 45
cycles of amplification (15 s at 95 °C and 1 min at 60 °C each)
with measurement of fluorescence at the end of each elongation
step. All assays included two negative controls (water) and a
dilution series of the plasmid pHIV-RT-Q that contained a 93-bp
fragment from the RT gene of HIV-1, as well as the endogenous
control plasmid pGAPDH-Q containing the complete gene of
human GAPDH. The detection of GAPDH RNAwas conducted
using a TaqMan Pre-Developed Assay Reagent containing a
VIC/TAMRA-labeled TaqMan probe (Applied Biosystems,
Foster City, CA). The standard curve of the threshold cycle
(CT) values was constructed for each PCR assay in order to
automatically calculate the sample quantities using the software
for data analysis (Livak and Schmittgen, 2001). All samples
were performed in triplicate.
Analysis of transcriptional activation
Preparation of nuclear extracts and electrophoretic mobility
shift assay (EMSA)
Nuclear extracts were prepared from 107 latently HIV-1-
infected OM-10.1 cells as described previously. The EMSAwas
based on the binding of nuclear NF-κB to a 32P-labeled NF-κB
consensus oligonucleotide (Promega). The NF-κB oligonucleo-
tide was labeled according to the manufacturer's protocol and
incubated for 30 min with 10 μg nuclear protein extract plus
binding buffer (Promega). Following incubation, the sample
was loaded on a 6% non-denaturing polyacrylamide gel in 0.5×
Tris/boric acid/EDTA (TBE) buffer. Gel shifts were examined
with a Phosphorimager (Molecular Dynamics, CA) and
analyzed using OptiQuant acquisition and analysis software
(Perkin-Elmer, CA).
The NF-κB transcription factor ELISA
The active form of NF-κB was quantified in OM-10.1 cell
extracts using the EZ-Detect™ NF-κB ELISA from Pierce.
Briefly, the nuclear extracts were incubated with an NF-κB
biotinylated-consensus sequence that is bound to the
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able to bind the consensus sequence that can be detected by a
specific NF-κB antibody. Incubation with a secondary HRP-
conjugated antibody and an appropriate chemiluminescent
substrate makes it possible to quantify NF-κB binding using a
luminocount (Packard).
Western blotting
Nuclear and cytoplasmic extracts from latently HIV-1-
infected OM-10.1 cells were prepared as described previously.
The protein concentration in the nuclear extracts was deter-
mined using the Bradford assay method. The protein concen-
tration in the cytoplasmic extracts was determined using the
BCA protein assay (Pierce). For western blot detection, protein
extracts were separated on 4–12% Novex Bis–Tris gels
purchased from Invitrogen (Merelbeke, Belgium). The proteins
were transferred onto polyvinylidene difluoride membranes
(Amersham Biosciences). The membrane was incubated over-
night at 4 °C for blocking in PBS containing 5% skim milk.
After having been washed 3 times with 0.1% Tween 20 in PBS,
the membrane was incubated for 1 h at room temperature with
antibodies. The rabbit polyclonal anti-IκBα antibody was
purchased from Santa Cruz Biotechnology. After three more
washes with the PBS-Tween 20 buffer, the membrane was
incubated for 1 h at room temperature with secondary
horseradish peroxidase (HRP)-conjugated antibodies (Santa
Cruz, CA). Detection was carried out using ECL Plus
chemiluminescent horseradish peroxidase substrate (Amersham
Biosciences).
Indirect immunofluorescence
Immunofluorescent detection of NF-κB was performed on
growing cells in LabTek II glass chamber slides (Nunc). Cells
were fixed by incubation with 4% formaldehyde in PBS for
10 min, washed with PBS and permeabilized with ice-cold
methanol. The cells were then blocked in PBS containing 10%
FCS and 20 mM ammonium chloride for 30 min and incubated
with monoclonal anti-NF-κB antibodies (used at a dilution
1:200), followed by Alexa-488-conjugated goat anti-mouse
antibody (Molecular Probes, Leiden, The Netherlands). After 3
final washes with PBS-FCS buffer, the cells were photographed
through a Zeiss Axiovert 40 CFL inverted microscope with LD
A-Plan 20×/0.30 objective using a Canon Powershot G5
camera.
Analysis of the HIV-1 chromatin structure and the transcription
process
Nuc-1 remodeling assay
The assay is based on nuclease digestion of purified nuclei
with restriction enzymes that cut the proviral DNA at the level of
nuc-1 positioning, whereas an undigested site in the proviral
DNA is used as internal control. The latently HIV-1-infected
OM-10.1 and U1 cells were cultured overnight in a 48-well plate
at a density of 400,000 cells per cup in the presence or the
absence of compound and/or TNF-α. Cells were collected by
centrifugation, washed twice with ice-cold phosphate-bufferedsaline (PBS) and resuspended in a buffer containing 10 mM
Tris–HCl (pH 7.4), 10 mM NaCl, 2 mM MgCl2 and 0.3 M
sucrose. Upon incubation of the cell pellet on ice for 5 min, an
equal volume of buffer supplemented with 0.2% NP40 was
added and further incubated for 5 min. Nuclei were pelleted and
resuspended in the appropriate buffers containing the restriction
enzymes. Following digestion of purified nuclei for 20 min at
37 °C, digestion reactions were stopped with a buffer containing
100 mM HEPES (pH 7.9), 200 mM NaCl, 2 mMMgCl2, 2 mM
EDTA and 1% SDS. Samples were solubilized for 1 h at 55 °C,
proteinase K (Roche Diagnostics Belgium) was added at
200 μg/ml and the samples were further incubated overnight at
55 °C. Upon RNase digestion for 1 h at 37 °C, digested DNAwas
extracted with phenol/chloroform/isoamylalcohol (Invitrogen,
Merelbeke, Belgium) and precipitated with ethanol containing
0.1 M sodium acetate (pH 5.2). Pelleted DNAwas resuspended
in nuclease-free water and analyzed for nuc-1 digestion by real-
time TaqMan PCR, using the plasmid pLTR-Q as standard and
pHIV-RT-Q as internal control. The PCR reactions were
performed in 96-well optical reaction plates with final volumes
of 25 μl per well. The PCR reaction contained 5 μl DNA sample
added to a mixture of 12.5 μl of TaqMan PCR master mix,
600 nM of each primer LTR-F, LTR-R, HIV-RT-F andHIV-RT-R
and 250 nM of the TaqMan LTR probe FAM-CCTCAA-
TAAAGCTTGCCTTGAGTGCTTCAA-TAMRA and the VIC/
TAMRA-labeled TaqMan HIV-RT probe. The standard curve of
the threshold cycle (CT) values was constructed for each PCR
assay in order to automatically calculate the sample quantities
using the software for data analysis (Livak and Schmittgen,
2001). All samples were performed in triplicate.
Quantitative chromatin immunoprecipitation (qChIP) assays
At least 500,000 latently HIV-1-infected cells were used for
each ChIP assay. Cells were fixed with formaldehyde to a final
concentration of 1% allowing cross-linking to proceed for
10 min at room temperature. The cross-linking reaction was
stopped by the addition of glycine at a final concentration of
0.125 M. Fixed cells were pelleted, washed twice in ice-cold
PBS and lysed in an appropriate lysis buffer (Upstate
Biotechnology, Lake Placid, NY). Chromatin was sheared to
an average length of 150–400 bp by sonication (20 pulses, 30 s
each) on ice using the XL2000 small volume Microson™
sonicator (Misonix, NY) and shearing was confirmed by agarose
gel electrophoresis analysis. Soluble chromatin was collected by
centrifugation and incubated on a rotating platform with the
indicated antibody at 4 °C overnight. Antibodies used in this
study include anti-histone H3, anti-acetyl-histone H3 and anti-
acetyl-histone H4 (Upstate Biotechnology), the antibodies α-
CTDH14 and 8WG16 (Covance, Richmond, CA) and the HIV-1
Tat antiserum obtained fromDr. Bryan Cullen through the AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH (Hauber et al., 1987). The immune complexes were
collected with salmon sperm DNA–protein A-agarose beads
(Upstate Biotechnology) and washed with the appropriate
buffers. Immunoprecipitated DNA was eluted using 1% SDS
in 0.1 MNaHCO3 and DNA cross-linking was reversed by a 4-h
incubation period with NaCl at 65 °C. Following proteinase K
236 M. Stevens et al. / Virology 365 (2007) 220–237digestion (Roche Molecular Biochemicals), DNAwas extracted
with phenol/chloroform /isoamylalcohol (Invitrogen) and pre-
cipitated with ethanol containing 0.1M sodium acetate (pH 5.2).
Pelleted DNA was resuspended in nuclease-free water and
analyzed by semi-quantitative PCR as well as real-time TaqMan
PCR using primer pair LTR-F and LTR-R. Semi-quantitative
PCR reactions contained 10 mM Tris–HCl (pH 8.3), 2 mM
MgCl2, 20 μM of each primer, 250 μM of each dATP, dGTP,
dCTP and dTTP and 1.5 U of Amplitaq polymerase (Applied
Biosystems). Following an initial denaturation step at 95 °C for
10min, DNAwas amplified for 40 cycles, each consisting of a 1-
min denaturing step at 95 °C, a 1-min annealing step at 60 °C and
a 2-min extension step at 72 °C. PCR products were resolved by
8% polyacrylamide gels and visualized by ethidium bromide
staining. Quantitative PCR, using pLTR-Q as standard, was
performed as previously described. Relative fold changes of
PCR products were normalized against the amounts of PCR
product obtained for input DNA. All values represent the
average of at least three independent experiments.
GFP transactivation assays
Transactivation studies in HeLa and HLtat cells were
performed by transfection of both cells lines in 0.7 ml cell
culture medium with 8 μg pHIV-GFPemd and 4 μg pSV2tat72
(for the non-Tat-expressing HeLa cells) plasmid DNA by
electroporation with an Easyject One electroporator (Cell one,
Belgium) in a 4-mm cuvette at 220 V; 1650 μF and infinite R.
The electroporated cells (70×103/well) were incubated in 96-
well microtiter plates for 24 h in the presence of varying
concentrations of the test compounds. Then, medium was
removed by gentle aspiration, and the monolayers were washed
with PBS. Inhibition of transactivation was measured with the
Fluorocount (Packard) by quantification of GFP reporter gene
activity at 24 h after transfection. The 50% inhibitory
concentration (IC50) was calculated as the inhibitor concentra-
tion that reduced GFP expression by 50%. Cytotoxicity of the
test compounds to the cells was determined in the same cell
cultures using the MTT method. The experiments to determine
the IC50 and CC50 values of the test compounds were performed
in quadruplicate.
For Jurkat and Jurkattat transfection, 30×10
6 cells were
resuspended in 400 μl of medium together with 40 μg of pHIV-
GFPemd and 20 μg pSV2tat72 (for the non-Tat-expressing
Jurkat cells) plasmid DNA and electroporated in a 4-mm cuvette
at 250 V, 1050 μF and infinite R. Then, electroporated cells
were resuspended in 2.5 ml of fresh medium and 100 μl of the
obtained cell suspension was transferred to 96-well plates
containing varying concentrations of the test compounds and
subsequently incubated for 24 h.
Kinase and histone acetyltransferase (HAT) assays
Protein kinases were assayed for their ability to phosphor-
ylate the appropriate peptide/protein substrate in the presence of
15 μM NR-818 and 10 μM ATP. Using the direct radiometric
approach, kinase activities were determined and expressed as %activity compared to the untreated control (Upstate Biotechnol-
ogy, Dundee, UK). HATs, such as p300 and P/CAF, were
assayed using the HAT assay kit from Upstate Biotechnology.
This assay is based on a non-radioactive indirect ELISA for the
detection of acetylated histone H3 or acetylated histone H4
substrate peptides using the HAT enzymes.
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